Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Loading...
Loading...

Upgrades

  • For AnaptysBio Inc ANAB, Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The stock has a 52-week-high of $36.06 and a 52-week-low of $18.20. At the end of the last trading period, AnaptysBio closed at $28.85.
  • According to Barclays, the prior rating for First Solar Inc FSLR was changed from Underweight to Equal-Weight. In the third quarter, First Solar showed an EPS of $0.46, compared to $0.42 from the year-ago quarter. At the moment, the stock has a 52-week-high of $148.20 and a 52-week-low of $59.60. First Solar closed at $145.57 at the end of the last trading period.
  • According to Morgan Stanley, the prior rating for Gogo Inc GOGO was changed from Underweight to Equal-Weight. For the second quarter, Gogo had an EPS of $0.17, compared to year-ago quarter EPS of $0.12. The stock has a 52-week-high of $23.69 and a 52-week-low of $11.57. At the end of the last trading period, Gogo closed at $14.22.
  • RBC Capital upgraded the previous rating for Norfolk Southern Corp NSC from Underperform to Sector Perform. Norfolk Southern earned $3.80 in the third quarter, compared to $3.06 in the year-ago quarter. The stock has a 52-week-high of $298.99 and a 52-week-low of $203.65. At the end of the last trading period, Norfolk Southern closed at $228.07.
  • JP Morgan upgraded the previous rating for Lennox International Inc LII from Underweight to Neutral. Lennox International earned $4.10 in the third quarter, compared to $3.40 in the year-ago quarter. The stock has a 52-week-high of $324.04 and a 52-week-low of $182.85. At the end of the last trading period, Lennox International closed at $233.57.
  • JP Morgan upgraded the previous rating for Carvana Co CVNA from Underweight to Neutral. Carvana earned $2.35 in the second quarter, compared to $0.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of $240.58 and a 52-week-low of $12.90. Carvana closed at $13.53 at the end of the last trading period.
  • According to JP Morgan, the prior rating for Monster Beverage Corp MNST was changed from Neutral to Overweight. For the second quarter, Monster Beverage had an EPS of $0.51, compared to year-ago quarter EPS of $0.75. The stock has a 52-week-high of $99.81 and a 52-week-low of $71.78. At the end of the last trading period, Monster Beverage closed at $93.72.

See all analyst ratings upgrades.

 

Downgrades

  • For Abiomed Inc ABMD, Piper Sandler downgraded the previous rating of Overweight to Neutral. For the second quarter, Abiomed had an EPS of $1.30, compared to year-ago quarter EPS of $1.03. The current stock performance of Abiomed shows a 52-week-high of $368.97 and a 52-week-low of $219.84. Moreover, at the end of the last trading period, the closing price was at $252.08.
  • For Varonis Systems Inc VRNS, Craig-Hallum downgraded the previous rating of Buy to Hold. Varonis Systems earned $0.05 in the third quarter, compared to $0.05 in the year-ago quarter. The stock has a 52-week-high of $51.60 and a 52-week-low of $22.92. At the end of the last trading period, Varonis Systems closed at $26.77.
  • B of A Securities downgraded the previous rating for Inovio Pharmaceuticals Inc INO from Neutral to Underperform. In the second quarter, Inovio Pharmaceuticals showed an EPS of $0.46, compared to $0.39 from the year-ago quarter. The current stock performance of Inovio Pharmaceuticals shows a 52-week-high of $5.27 and a 52-week-low of $1.38. Moreover, at the end of the last trading period, the closing price was at $2.16.
  • According to Argus Research, the prior rating for Skechers USA Inc SKX was changed from Buy to Hold. For the third quarter, Skechers USA had an EPS of $0.55, compared to year-ago quarter EPS of $0.66. At the moment, the stock has a 52-week-high of $49.89 and a 52-week-low of $31.28. Skechers USA closed at $34.43 at the end of the last trading period.
  • Oppenheimer downgraded the previous rating for TuSimple Holdings Inc TSP from Outperform to Perform. For the third quarter, TuSimple Hldgs had an EPS of $0.50, compared to year-ago quarter EPS of $0.54. The current stock performance of TuSimple Hldgs shows a 52-week-high of $37.24 and a 52-week-low of $3.21. Moreover, at the end of the last trading period, the closing price was at $3.43.
  • For Ventas Inc VTR, Raymond James downgraded the previous rating of Strong Buy to Outperform. In the second quarter, Ventas showed an EPS of $0.72, compared to $0.73 from the year-ago quarter. At the moment, the stock has a 52-week-high of $64.02 and a 52-week-low of $35.33. Ventas closed at $39.13 at the end of the last trading period.
  • For Steven Madden Ltd SHOO, Wedbush downgraded the previous rating of Outperform to Neutral. In the second quarter, Steven Madden showed an EPS of $0.63, compared to $0.48 from the year-ago quarter. The stock has a 52-week-high of $49.84 and a 52-week-low of $26.36. At the end of the last trading period, Steven Madden closed at $29.87.
  • According to Barclays, the prior rating for Principal Financial Group Inc PFG was changed from Overweight to Equal-Weight. Principal Finl Gr earned $1.69 in the third quarter, compared to $1.69 in the year-ago quarter. The stock has a 52-week-high of $88.52 and a 52-week-low of $61.05. At the end of the last trading period, Principal Finl Gr closed at $88.13.
  • Canaccord Genuity downgraded the previous rating for Argo Blockchain PLC ARBK from Buy to Hold. For the second quarter, Argo Blockchain had an EPS of $0.82, compared to year-ago quarter EPS of $0.03. At the moment, the stock has a 52-week-high of $13.14 and a 52-week-low of $0.88. Argo Blockchain closed at $1.11 at the end of the last trading period.
  • For Varonis Systems Inc VRNS, Wells Fargo downgraded the previous rating of Overweight to Underweight. For the third quarter, Varonis Systems had an EPS of $0.05, compared to year-ago quarter EPS of $0.05. At the moment, the stock has a 52-week-high of $51.60 and a 52-week-low of $22.92. Varonis Systems closed at $26.77 at the end of the last trading period.
  • According to Deutsche Bank, the prior rating for Emerson Electric Co EMR was changed from Buy to Hold. In the fourth quarter, Emerson Electric showed an EPS of $1.53, compared to $1.21 from the year-ago quarter. The stock has a 52-week-high of $100.00 and a 52-week-low of $72.41. At the end of the last trading period, Emerson Electric closed at $86.60.
  • For Charles Schwab Corp SCHW, Credit Suisse downgraded the previous rating of Outperform to Neutral. Charles Schwab earned $1.10 in the third quarter, compared to $0.84 in the year-ago quarter. At the moment, the stock has a 52-week-high of $96.24 and a 52-week-low of $59.35. Charles Schwab closed at $79.67 at the end of the last trading period.
  • According to Cowen & Co., the prior rating for Instil Bio Inc TIL was changed from Outperform to Market Perform. In the second quarter, Instil Bio showed an EPS of $0.46, compared to $0.27 from the year-ago quarter. At the moment, the stock has a 52-week-high of $18.97 and a 52-week-low of $3.11. Instil Bio closed at $3.30 at the end of the last trading period.
  • According to Canaccord Genuity, the prior rating for Stryker Corp SYK was changed from Buy to Hold. In the third quarter, Stryker showed an EPS of $2.12, compared to $2.20 from the year-ago quarter. At the moment, the stock has a 52-week-high of $280.43 and a 52-week-low of $188.84. Stryker closed at $229.24 at the end of the last trading period.
  • According to RBC Capital, the prior rating for Clearwater Paper Corp CLW was changed from Outperform to Sector Perform. Clearwater Paper earned $1.83 in the third quarter, compared to $0.55 in the year-ago quarter. The current stock performance of Clearwater Paper shows a 52-week-high of $46.48 and a 52-week-low of $25.07. Moreover, at the end of the last trading period, the closing price was at $44.48.
  • According to RBC Capital, the prior rating for Union Pacific Corp UNP was changed from Sector Perform to Underperform. In the third quarter, Union Pacific showed an EPS of $3.19, compared to $2.57 from the year-ago quarter. The stock has a 52-week-high of $278.94 and a 52-week-low of $183.70. At the end of the last trading period, Union Pacific closed at $197.14.

See all analyst ratings downgrades.

 

Initiations

  • Cowen & Co. initiated coverage on Legend Biotech Corp LEGN with an Outperform rating. Legend Biotech earned $0.24 in the first quarter, compared to $0.30 in the year-ago quarter. The stock has a 52-week-high of $57.67 and a 52-week-low of $30.75. At the end of the last trading period, Legend Biotech closed at $49.82.
  • With a Buy rating, BTIG initiated coverage on Rocket Pharmaceuticals Inc RCKT. The price target seems to have been set at $35.00 for Rocket Pharmaceuticals. For the second quarter, Rocket Pharmaceuticals had an EPS of $0.83, compared to year-ago quarter EPS of $0.55. The stock has a 52-week-high of $24.18 and a 52-week-low of $7.57. At the end of the last trading period, Rocket Pharmaceuticals closed at $18.66.
  • With a Hold rating, Loop Capital initiated coverage on ACADIA Pharmaceuticals Inc ACAD. The price target seems to have been set at $17.00 for ACADIA Pharmaceuticals. For the second quarter, ACADIA Pharmaceuticals had an EPS of $0.21, compared to year-ago quarter EPS of $0.27. The current stock performance of ACADIA Pharmaceuticals shows a 52-week-high of $28.05 and a 52-week-low of $12.24. Moreover, at the end of the last trading period, the closing price was at $16.03.
  • Loop Capital initiated coverage on Compass Pathways PLC CMPS with a Buy rating. The price target for Compass Pathways is set to $34.00. Compass Pathways earned $0.50 in the second quarter, compared to $0.44 in the year-ago quarter. The current stock performance of Compass Pathways shows a 52-week-high of $23.22 and a 52-week-low of $6.54. Moreover, at the end of the last trading period, the closing price was at $10.54.
  • With a Buy rating, Loop Capital initiated coverage on Axsome Therapeutics Inc AXSM. The price target seems to have been set at $95.00 for Axsome Therapeutics. Axsome Therapeutics earned $1.06 in the second quarter, compared to $0.86 in the year-ago quarter. At the moment, the stock has a 52-week-high of $71.98 and a 52-week-low of $20.63. Axsome Therapeutics closed at $45.15 at the end of the last trading period.
  • Truist Securities initiated coverage on Evolent Health Inc EVH with a Hold rating. The price target for Evolent Health is set to $33.00. In the second quarter, Evolent Health showed an EPS of $0.10, compared to $0.02 from the year-ago quarter. At the moment, the stock has a 52-week-high of $39.78 and a 52-week-low of $21.36. Evolent Health closed at $31.81 at the end of the last trading period.
  • Alliance Global Partners initiated coverage on Reviva Pharmaceuticals Holdings Inc RVPH with a Buy rating. The price target for Reviva Pharmaceuticals is set to $16.00. In the second quarter, Reviva Pharmaceuticals showed an EPS of $0.29, compared to $0.12 from the year-ago quarter. The current stock performance of Reviva Pharmaceuticals shows a 52-week-high of $4.50 and a 52-week-low of $0.53. Moreover, at the end of the last trading period, the closing price was at $3.92.
  • B. Riley Securities initiated coverage on PDS Biotechnology Corp PDSB with a Buy rating. The price target for PDS Biotechnology is set to $10.00. In the second quarter, PDS Biotechnology showed an EPS of $0.20, compared to $0.03 from the year-ago quarter. The current stock performance of PDS Biotechnology shows a 52-week-high of $8.47 and a 52-week-low of $2.89. Moreover, at the end of the last trading period, the closing price was at $5.24.
  • BMO Capital initiated coverage on AMC Entertainment Holdings Inc AMC with an Outperform rating. The price target for AMC Entertainment is set to $6.50. AMC Entertainment earned $0.20 in the second quarter, compared to $0.71 in the year-ago quarter. The current stock performance of AMC Entertainment shows a 52-week-high of $34.33 and a 52-week-low of $5.47. Moreover, at the end of the last trading period, the closing price was at $6.66.
  • Credit Suisse initiated coverage on Tronox Holdings PLC TROX with an Underperform rating. The price target for Tronox Holdings is set to $10.00. For the third quarter, Tronox Holdings had an EPS of $0.69, compared to year-ago quarter EPS of $0.72. The stock has a 52-week-high of $25.95 and a 52-week-low of $11.14. At the end of the last trading period, Tronox Holdings closed at $12.00.
  • With a Buy rating, Loop Capital initiated coverage on Karuna Therapeutics Inc KRTX. The price target seems to have been set at $288.00 for Karuna Therapeutics. In the second quarter, Karuna Therapeutics showed an EPS of $2.17, compared to $1.17 from the year-ago quarter. At the moment, the stock has a 52-week-high of $278.25 and a 52-week-low of $92.26. Karuna Therapeutics closed at $219.34 at the end of the last trading period.
  • Loop Capital initiated coverage on Sage Therapeutics Inc SAGE with a Hold rating. The price target for Sage Therapeutics is set to $41.00. For the second quarter, Sage Therapeutics had an EPS of $2.13, compared to year-ago quarter EPS of $1.83. The current stock performance of Sage Therapeutics shows a 52-week-high of $45.74 and a 52-week-low of $27.36. Moreover, at the end of the last trading period, the closing price was at $37.66.
  • Credit Suisse initiated coverage on The Chemours Co CC with an Underperform rating. The price target for Chemours is set to $24.00. Chemours earned $1.24 in the third quarter, compared to $1.27 in the year-ago quarter. At the moment, the stock has a 52-week-high of $44.95 and a 52-week-low of $22.56. Chemours closed at $28.63 at the end of the last trading period.
  • With a Neutral rating, HC Wainwright & Co. initiated coverage on Horizon Therapeutics PLC HZNP. The price target seems to have been set at $74.00 for Horizon Therapeutics. Horizon Therapeutics earned $1.07 in the second quarter, compared to $1.62 in the year-ago quarter. The stock has a 52-week-high of $117.49 and a 52-week-low of $57.84. At the end of the last trading period, Horizon Therapeutics closed at $62.32.
  • Jefferies initiated coverage on Edap TMS SA EDAP with a Buy rating. The price target for Edap TMS is set to $11.00. Edap TMS earned $0.06 in the second quarter, compared to $0.02 in the year-ago quarter. The stock has a 52-week-high of $9.52 and a 52-week-low of $5.54. At the end of the last trading period, Edap TMS closed at $9.48.
  • EF Hutton initiated coverage on Biomea Fusion Inc BMEA with a Buy rating. The price target for Biomea Fusion is set to $27.00. For the second quarter, Biomea Fusion had an EPS of $0.59, compared to year-ago quarter EPS of $0.33. The current stock performance of Biomea Fusion shows a 52-week-high of $14.20 and a 52-week-low of $2.84. Moreover, at the end of the last trading period, the closing price was at $11.00.
  • JP Morgan initiated coverage on NorthWestern Corp NWE with a Neutral rating. The price target for NorthWestern is set to $55.00. In the third quarter, NorthWestern showed an EPS of $0.42, compared to $0.65 from the year-ago quarter. At the moment, the stock has a 52-week-high of $63.06 and a 52-week-low of $48.68. NorthWestern closed at $52.83 at the end of the last trading period.
  • With a Buy rating, EF Hutton initiated coverage on Lantern Pharma Inc LTRN. The price target seems to have been set at $11.00 for Lantern Pharma. For the second quarter, Lantern Pharma had an EPS of $0.41, compared to year-ago quarter EPS of $0.21. At the moment, the stock has a 52-week-high of $8.30 and a 52-week-low of $4.19. Lantern Pharma closed at $4.19 at the end of the last trading period.
  • With a Buy rating, EF Hutton initiated coverage on Exelixis Inc EXEL. The price target seems to have been set at $28.00 for Exelixis. The stock has a 52-week-high of $23.40 and a 52-week-low of $14.87. At the end of the last trading period, Exelixis closed at $16.58.
  • EF Hutton initiated coverage on Regeneron Pharmaceuticals Inc REGN with a Buy rating. The price target for Regeneron Pharmaceuticals is set to $851.00. In the second quarter, Regeneron Pharmaceuticals showed an EPS of $9.77, compared to $25.80 from the year-ago quarter. The current stock performance of Regeneron Pharmaceuticals shows a 52-week-high of $761.04 and a 52-week-low of $538.01. Moreover, at the end of the last trading period, the closing price was at $748.75.
  • With a Buy rating, EF Hutton initiated coverage on Intellia Therapeutics Inc NTLA. The price target seems to have been set at $130.00 for Intellia Therapeutics. For the second quarter, Intellia Therapeutics had an EPS of $1.33, compared to year-ago quarter EPS of $1.01. The current stock performance of Intellia Therapeutics shows a 52-week-high of $119.65 and a 52-week-low of $37.08. Moreover, at the end of the last trading period, the closing price was at $52.78.
  • With a Buy rating, EF Hutton initiated coverage on Jasper Therapeutics Inc JSPR. The price target seems to have been set at $4.00 for Jasper Therapeutics. For the second quarter, Jasper Therapeutics had an EPS of $0.29, compared to year-ago quarter EPS of $4.00. At the moment, the stock has a 52-week-high of $8.12 and a 52-week-low of $0.71. Jasper Therapeutics closed at $0.73 at the end of the last trading period.
  • Stifel initiated coverage on OptimizeRx Corp OPRX with a Buy rating. The price target for OptimizeRx is set to $19.00. For the second quarter, OptimizeRx had an EPS of $0.04, compared to year-ago quarter EPS of $0.10. The stock has a 52-week-high of $64.22 and a 52-week-low of $13.33. At the end of the last trading period, OptimizeRx closed at $15.41.

See all analyst ratings initiations.

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: UpgradesDowngradesInitiationIntraday UpdateAnalyst RatingsBZI-Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...